Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[Q]: Republican Coalition Party (in Estonian: Vabariiklaste Koonderakond) 22.09.1990 -- 21.11.1992 Leo Starkov Estonian Christian-Democratic Union (Eesti Kristlik-Demokraatlik Liit) 29.08.1989 -- 21.11.1992 Illar Hallaste Estonian Christian-Democratic Party (Eesti Kristlik-Demokraatlik Erakond) 23.07.1988 -- 21.11.1992 Aivar Kala Estonian Conservative People's Party (Eesti Konservatiivne Rahvaerakond) 09.06.1990 -- 21.11.1992 Enn Tarto Estonian National Independence Party (Eesti Rahvusliku Soltumatuse Partei) 20.08.1988 -- 18.07.1993 Lagle Parek 18.07.1993 -- 27.11.1993 Ants Erm 27.11.1993 -- 02.12.1995 Tunne-Valdo Kelam Estonian National Coalition Party 'Pro Patria' (Eesti Rahvuslik Koonderakond Isamaa) 21.11.1992 -- 02.12.1995 Mart Laar Estonian Pro Patria Union (Eesti Isamaaliit) 02.12.1995 -- 24.10.1998 Toivo Jurgenson 24.10.1998 -- 14.12.2002 Mart Laar 14.12.2002 -- 16.04.2005 Tunne-Valdo Kelam 16.04.2005 -- 04.06.2006 Tonis Lukas Res Publica Party (Erakond Res Publica) 08.12.2001 -- 24.08.2002 Rein Taagepera 24.08.2002 -- 04.06.2005 Juhan Parts 04.06.2005 -- 04.06.2006 Taavi Veskimagi Pro Patria and Res Publica Union (Isamaa ja Res Publica Liit) 04.06.2006 -- 26.05.2007 Taavi Veskimagi (Res Publica) / Tonis Lukas (Pro Patria) 26.05.2007 -- 28.01.2012 Mart Laar 28.01.2012 -- 06.06.2015 Urmas Reinsalu 06.06.2015 --
[A]: Who led Pro Patria and Res Publica Union?


[Q]: Marjanovic took over Ciguli Miguli only after his proposal for Nikola Tesla, a biography of the famous engineer and inventor, had been rejected by Jadran Film.
[A]: What production company was involved in Ciguli Miguli?


[Q]: Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture which leads to increased fracture risk. Some of the drugs available to date have shown reductions in vertebral and non-vertebral fracture risk. However, in the ageing population of industrialised countries, still more fractures happen today than are avoided, which highlights the large medical need for new treatment options, models, and strategies. Recent insights into bone biology, have led to a better understanding of bone cell functions and crosstalk between osteoblasts, osteoclasts, and osteocytes at the molecular level. In the future, the armamentarium against osteoporotic fractures will likely be enriched by (1.) new bone anabolic substances such as antibodies directed against the endogenous inhibitors of bone formation sclerostin and dickkopf-1, PTH and PTHrp analogues, and possibly calcilytics; (2.) new inhibitors of bone resorption such as cathepsin K inhibitors which may suppress osteoclast function without impairing osteoclast viability and thus maintain bone formation by preserving the osteoclast-osteoblast crosstalk, and denosumab, an already widely available antibody against RANKL which inhibits osteoclast formation, function, and survival; and (3.) new therapeutic strategies based on an extended understanding of the pathophysiology of osteoporosis which may include sequential therapies with two or more bone active substances aimed at optimising the management of bone capital acquired during adolescence and maintained during adulthood in terms of both quantity and quality. Finally, one of the future challenges will be to identify those patients and patient populations expected to benefit the most from a given drug therapy or regimen. The WHO fracture risk assessment tool FRAX® and improved access to bone mineral density measurements by DXA will play a key role in this regard.
[A]:
To the ligand of which receptors does Denosumab (Prolia) bind?